Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Dean F BajorinJ Alfred WitjesJürgen E GschwendMichael SchenkerBegoña P ValderramaYoshihiko TomitaAristotelis BamiasThierry LebretShahrokh F ShariatSe Hoon ParkDingwei YeMads AgerbaekDeborah EntingRay McDermottPablo GajateAvivit PeerMatthew I MilowskyAlexander NosovJoão Neif AntonioKrzysztof TupikowskiLaurence TomsBruce S FischerAnila QureshiSandra ColletteKeziban Unsal-KacmazEdward BroughtonDimitrios ZardavasHenry B KoonMatthew D GalskyPublished in: The New England journal of medicine (2021)
In this trial involving patients with high-risk muscle-invasive urothelial carcinoma who had undergone radical surgery, disease-free survival was longer with adjuvant nivolumab than with placebo in the intention-to-treat population and among patients with a PD-L1 expression level of 1% or more. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 274 ClinicalTrials.gov number, NCT02632409.).